Septerna, Inc. (SEPN) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $46.00K; Additional Paid in Capital, Common StockUSD $576.86M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.26M; Retained Earnings (Accumulated Deficit)USD $-188.92M.
- 2026-03-31: Common Stock, Value, IssuedUSD $45.00K; Additional Paid in Capital, Common StockUSD $554.87M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-569.00K; Retained Earnings (Accumulated Deficit)USD $-175.89M.
- 2025-12-31: Common Stock, Value, IssuedUSD $45.00K; Additional Paid in Capital, Common StockUSD $548.52M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $617.00K; Retained Earnings (Accumulated Deficit)USD $-167.25M.
- 2025-09-30: Common Stock, Value, IssuedUSD $45.00K; Additional Paid in Capital, Common StockUSD $544.83M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $375.00K; Retained Earnings (Accumulated Deficit)USD $-156.51M.
Septerna, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|
| 2026-06-30 | $46.00K | $576.86M | $-1.26M | $-188.92M | $386.72M | 3 month · $5.07M |
| 2026-03-31 | $45.00K | $554.87M | $-569.00K | $-175.89M | $378.46M | 3 month · $6.01M |
| 2025-12-31 | $45.00K | $548.52M | $617.00K | $-167.25M | $381.93M | 12 month · $8.48M |
| 2025-09-30 | $45.00K | $544.83M | $375.00K | $-156.51M | $388.73M | 3 month · $2.53M |
| 2025-06-30 | $45.00K | $542.02M | $176.00K | $-164.69M | $377.56M | 3 month · $1.81M |
| 2025-03-31 | $44.00K | $539.87M | $198.00K | $-139.85M | $400.27M | 3 month · $1.48M |
| 2024-12-31 | $44.00K | $538.32M | $56.00K | $-118.37M | $420.05M | 12 month · $3.15M |
| 2024-09-30 | $3.00K | $10.12M | $176.00K | $-97.71M | $-87.41M | 3 month · $683.00K |
| 2024-06-30 | (m) | (m) | (m) | (m) | $-67.76M | 3 month · $628.00K |
| 2024-03-31 | (m) | (m) | (m) | (m) | $-51.89M | 3 month · $577.00K |
| 2023-12-31 | $3.00K | $8.20M | $0.00 | $-46.58M | $-38.37M | 12 month · $1.62M |
| 2023-09-30 | (m) | (m) | (m) | (m) | $-73.85M | 3 month · $347.00K |
| 2023-06-30 | (m) | (m) | (m) | (m) | $-63.26M | 3 month · $355.00K |
| 2023-03-31 | (m) | (m) | (m) | (m) | $-53.02M | 3 month · $343.00K |
| 2022-12-31 | (m) | (m) | (m) | (m) | $-44.20M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |